Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medical College of Wisconsin

http://www.mcw.edu/mcw/home.htm#.UVHbDRzvs-U

Latest From Medical College of Wisconsin

Verve Not Ready To Pull Plug On Anti-PCSK9 Gene Editing Candidate

The company told Scrip that the sixth patient with elevated liver enzymes and low platelets recovered after hospital observation and oral steroids, and it may still continue VERVE-101’s development.

Gene Therapy Clinical Trials

Silence Open To A Partner But Ready To Go It Alone On Lp(a) Drug

The company said it has the financing to move forward with a Phase III program for zerlasiran in patients with high lipoprotein(a) at high risk of atherosclerotic cardiovascular disease.

Cardiovascular Clinical Trials

The ‘Biggest’ Dealmakers Of 2023 Were Not The Busiest

Eli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.

Deals M & A

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

The company claims its gene editing tech is the most potent yet – and is joining others in making established cardiovascular disease gene PCSK9 its first therapeutic target

Companies Gene Therapy
See All

Company Information

  • Industry
  • Academic and Research Institutions
UsernamePublicRestriction

Register